UC DAVIS (US) — Neurosurgeons are using a new stem cell therapy to promote the growth of bone tissue following the removal of cervical discs—to help treat chronic, debilitating pain.
Removal of the cervical disc relieves pain by eliminating friction between the vertebrae and/or nerve compression. Spinal fusion is used in surgery for degenerative disc disease, where the cushioning cartilage has worn away, leaving bone to rub against bone, and herniated discs, where the discs pinch or compress nerves.
The procedure was performed by Kee Kim and Rudolph Schrot, both associate professors of neurosurgery at the University of California, Davis. They used bone marrow-derived adult stem cells to promote the growth of the bone tissue essential for spinal fusion following surgery, as part of a nationwide, multicenter clinical trial of the therapy.
“We hope that this investigational procedure eventually will help those who undergo spinal fusion in the back as well as in the neck,” says Kim. “And the knowledge gained about stem cells also will be applied in the near future to treat without surgery those suffering from back pain.”
“This is an exciting clinical trial to test the ability of the bone-forming stem cells from healthy donors to help patients with spinal disease,” says Jan Nolta, director of the UC Davis Institute for Regenerative Cures.
“For the past 50 years, bone marrow-derived stem cells have been used to rebuild patients’ blood-forming systems. We know that subsets of stem cells from the marrow also can robustly build bone. Their use now to promote vertebral fusion is a new and extremely promising area of clinical study,” she adds.
The stem cell procedure took place early in August. The patient was a 53-year-old male from the Sacramento region with degenerative disc disease.
In the surgery, called an anterior cervical discectomy, a cervical disc or multiple discs are removed via an incision in the front of the neck. The investigational stem cell therapy then is applied to promote fusion of the vertebrae across the space created by the disc removal.
The stem cells are derived from a healthy single adult donor’s bone marrow, and thus are very homogenous, Kim explains. They are grown in culture to high concentration with minimal chance for rejection by the recipient, he adds.
Adequate spinal fusion fails to occur in 8 to 35 percent or more of patients, and persistent pain occurs in up to 60 percent of patients with fusion failure, which often necessitates additional surgery.
“A lack of effective new bone growth after spine fusion surgery can be a significant problem, especially in surgeries involving multiple spinal segments,” says Schrot, co-principal investigator for the study. “This new technology may help patients grow new bone, and it avoids harvesting a bone graft from the patient’s own hip or using bone from a deceased donor.”
Current methods of promoting spinal fusion include implanting bone tissue from the patient’s hip or a cadaver to encourage bone regrowth as well as implanting bone growth-inducing proteins. However, the Food and Drug Administration has not approved the use of bone morphogenetic proteins for cervical spinal fusion. Their use has been associated with life-threatening complications, particularly in the neck.
The leading-edge stem cell procedure is part of a prospective, randomized, single-blinded controlled study to evaluate the safety and preliminary efficacy of an investigational therapy: modified bone marrow-derived stem cells combined with the use of a delivery device as an alternative to promote and maintain spinal fusion.
The study includes 10 investigational centers nationwide. The UC Davis Department of Neurological Surgery anticipates enrolling up to 10 study participants who will be treated with the stem cell therapy and followed for 36 months after their surgeries. A total of 24 participants will be enrolled nationwide.
The study is one of several clinical trials under way in the UC Davis Spine Center and led by Kim. He anticipates launching a clinical trial soon to study the safety of injecting stem cells into disc tissue to repair degenerated discs.
The current study is sponsored by Mesoblast, Ltd., of Melbourne, Australia, which is developing adult universal-donor stem cell products built upon the discovery of adult-derived mesenchymal precursor cells. Kim and Schrot will not be compensated for their participation in the study.
More news from UC Davis: www.news.ucdavis.edu/